Background: The recent development of multiple targeted agents for metastatic renal cell carcinoma (mRCC) has changed the treatment paradigm; hence the benefit and optimal timing of cytoreductive nephrectomy is being reevaluated. Objective: To determine primary tumor response to treatment with targeted agents in patients with mRCC. Design, setting, and participants: We reviewed the clinical and radiographic data of all mRCC patients seen at our institution between November 2004 and December 2009 without prior systemic treatment who received targeted therapy with their primary tumor in situ. Measurements: Two independent reviewers measured the diameter of primary and metastatic tumors at baseline and subsequent scans, using Response Evaluation Criteria Solid Tumors (RECIST) v.1.1 to assess disease response. Results and limitations: We identified 168 consecutive patients with a median 15 mo of follow-up and a median maximum tumor diameter of 9.6 cm. Median maximum primary tumor response was -7.1% (interquartile range: -14.0 to -0.1). A total of 61 patients had multiple studies available for evaluation. In 43 patients with <10% decrease in primary tumor within in the first 60 d, median maximum response was -7.2% at 154 d versus -24.5% maximum response at 174.5 d for 18 patients with >= 10% decrease in primary tumor during the initial 60 d. Conclusions: Decrease in primary tumor diameter >30% while on targeted therapy for mRCC is rare, with most patients demonstrating minimal or no decrease in primary tumor diameter. Early response predicts a better overall primary tumor response. (C) 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
机构:
Univ New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Univ New S Wales, Sch Med Sci, Sydney, NSW, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Webber, K.
Cooper, A.
论文数: 0引用数: 0
h-index: 0
机构:
Australian Natl Univ, Canberra Hosp, Med Oncol Unit, Canberra, ACT, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Cooper, A.
论文数: 引用数:
h-index:
机构:
Kleiven, H.
Yip, D.
论文数: 0引用数: 0
h-index: 0
机构:
Australian Natl Univ, Canberra Hosp, Med Oncol Unit, Canberra, ACT, Australia
Australian Natl Univ, ANU Med Sch, Canberra, ACT, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Yip, D.
Goldstein, D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
机构:
Univ New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Univ New S Wales, Sch Med Sci, Sydney, NSW, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Webber, K.
Cooper, A.
论文数: 0引用数: 0
h-index: 0
机构:
Australian Natl Univ, Canberra Hosp, Med Oncol Unit, Canberra, ACT, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Cooper, A.
论文数: 引用数:
h-index:
机构:
Kleiven, H.
Yip, D.
论文数: 0引用数: 0
h-index: 0
机构:
Australian Natl Univ, Canberra Hosp, Med Oncol Unit, Canberra, ACT, Australia
Australian Natl Univ, ANU Med Sch, Canberra, ACT, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Yip, D.
Goldstein, D.
论文数: 0引用数: 0
h-index: 0
机构:
Univ New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, AustraliaUniv New S Wales, Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia